Public health authorities face an intensifying crisis as a practice known as “bluetoothing” or “hotspotting” enters global health discussions surrounding a surge in HIV infections. The World Health Organization (OMS) detailed that Fiji recorded 1,538 new HIV cases during 2024 and an additional 1,226 cases in the first six months of 2025. The World Health Organization alerted in December 2025 by the epidemic of VIH of more rapid growth in the world, in Fiji, in the context detected of people who inject drugs, provoking a greater risk of transmission of the virus. Fiji declared a national HIV crisis. Approximately one of every 60 adults in the archipelago lives with the virus, compared to one of every 167 five years ago. In this territory, infections multiplied by 10 from 2014 through 2024, affecting with special harshness youth from 15 to 34 years old. The Ministry of Health stated to the mentioned media that effectively this practice was one of the factors that most drove the increase of the cases, while UNAIDS alerted about the major crisis in the response to HIV in decades, increasing risks for millions.
Global Spread Across Oceania, Africa, and Asia
While Fiji deals with an infection rate where roughly one in 60 adults lives with the virus, similar drug consumption methods appear in distinct international regions. In Africa, nations including South Africa, Lesotho, Zimbabwe, and Tanzania report variations of the practice, sometimes referred to as flashblood in Tanzania.
Péptidos para bajar de peso: ¿sí, no y por qué? Esto dice la cienciahttps://t.co/vaSPvw9M30
Evaluating the Evidence and Health Risks
Medical specialists explain that the concentration of drugs remaining in extracted blood is limited, producing a reduced effect while exposing users to biological hazards. Direct blood transfer allows pathogens like HIV and hepatitis B and C to enter a recipient’s bloodstream. Beyond viral transmission, physicians warn that mismatched blood types can provoke immune responses, severe cardiac stress, and fatal outcomes, alongside bacterial infections such as septicemia, abscesses, and endocarditis. A rapid assessment by the World Health Organization evaluating people who inject drugs in Fiji found that two of 56 surveyed individuals admitted to practicing this conduct and four affirmed having witnessed it, though all participants reported reusing injection equipment due to shortages of sterile supplies. Experts cited by media such as BBC, New York Times, and Biobio Chile indicated that this practice arises as a response to extreme poverty, the high cost of narcotics, and the lack of access to sterile injection material, with academics concurring that consumers seek to stretch a single dose or mitigate withdrawal symptoms by sharing the drug residue remaining in the bloodstream. UNAIDS noted that it does not constitute a widespread global trend.
Frequently Asked Questions About Bluetoothing
What is bluetoothing and why do drug users attempt it?
Bluetoothing, also called hotspotting, occurs when someone who has injected a substance draws blood into the syringe and injects it into another person. Users in impoverished conditions often attempt this method to stretch a drug dose or mitigate withdrawal symptoms using blood residues, with some individuals utilizing it with the intention of obtaining an additional effect and making injectable drugs last longer.
How does the World Health Organization connect the practice to Fiji’s HIV crisis?
The OMS reported that 48 percent of individuals who initiated HIV treatment in Fiji during 2024 were people who inject drugs. While health officials identify sharing injection equipment as a primary factor, formal assessments indicate little evidence that bluetoothing is widespread in the communities studied.
What medical complications arise from sharing blood via syringes?
Incompatible blood transfers can trigger immune reactions that lead to fatal outcomes.
Combating the Epidemic and Providing Treatment
To combat bluetoothing, health organizations and different NGOs worldwide have led programs exchanging sterile needles and syringes to discourage the reuse of equipment, alongside access to free and confidential HIV and hepatitis testing, facilitating Antiretroviral Therapy (ART) and Post-Exposure Prophylaxis (PEP) within the first 72 hours. Information and medical care without stigma are part of the necessary measures to reduce transmissions and facilitate that people at risk receive timely prevention and treatment.
Related reading